As AAV-based gene therapies continue to advance toward broader indications, manufacturing efficiency, consistency, and scalability are becoming critical enablers of commercial viability. Traditional transient transfection approaches introduce supply chain complexity, batch-to-batch variability, and scaling limitations, prompting increasing interest in stable producer cell line (PCL)–based manufacturing.
Transitioning from transient transfection to a PCL represents a manufacturing process change, not simply a material change, and must be evaluated within the framework of ICH Q5E and applicable global regulatory guidance. Analytical comparability serves as the foundation for assessing potential impacts to product quality, safety, and efficacy, and informs the need for additional nonclinical or clinical bridging studies.
In this fireside chat, industry experts will explore practical considerations for adopting PCL-based processes, including how the timing of the transition influences regulatory expectations and development risk. Panelists will also discuss the role of robust analytical strategies in supporting comparability, as well as the potential of PCL platforms to deliver improved productivity, consistency, and scalability, supporting long-term cost reduction and manufacturing robustness.
Watch this webinar to:
- Understand the distinction between a manufacturing process change and a material change when transitioning to a producer cell line, and how that distinction affects your comparability strategy
- Gain a framework for determining when analytical comparability data alone is sufficient versus when nonclinical or clinical bridging may be required
- Assess how transition timing affects regulatory risk, development burden, and the path toward scalable, cost-efficient AAV manufacturing
- Apply practical considerations for engaging CMC, regulatory, process development, and CDMO partners when planning and executing a platform transition
